MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Charts
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
GLPG stock logo

GLPG

Galapagos N.V.

$27.98
0.47
 (1.71%)
Exchange:  NASDAQ
Market Cap:  1.844B
Shares Outstanding:  5.939M
Delayed data
Calculate GLPG Intrinsic Value
5-year outlook →
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Biotechnology
   
CEO:  Henry O. Gosebruch
Full Time Employees:  452
Address: 
Generaal De Wittelaan L11 A3
Mechelen
2800
BE
Website:  https://lakefrontbio.com
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.

Click to read more…

Revenue Segmentation

MARKETSnap
MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/05/07 — 1 quarter 2026

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue239,724275,6491,112,248
Gross Profit239,724240,7861,082,512
EBITDA51,03743,325358,963
Operating Income-88,263-188,338501,391
Net Income211,69774,082320,884

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets4,357,3964,135,7193,405,068.168
Total Liabilities1,561,8301,238,780170,577.370
Total Stockholders Equity2,795,5662,896,9393,234,490.797
Total Debt9,59611,72212,095.848
Cash and Cash Equivalents166,80364,23987,830.602

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow-405,970-320,0260
Capital Expenditure-19,273-82,1100
Free Cash Flow-425,243-402,1360
Net Income211,69774,082320,900
Net Change in Cash-341,307-102,571-64,239

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)38,182.798Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)60,210.796Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)49,996.751Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)3,823.585Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)6,029.445Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)5,006.622Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)-232,063.415Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)-127,038.182Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)-183,365.028Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)12,359.083Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)19,489.149Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)16,183.047Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)-2.780Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)-1.930Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)-3.520Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)2Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)1Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
298.167M  ?P/S
 (TTM)
: 
1.59
?Net Income
 (TTM)
: 
80.134M  ?P/E
 (TTM)
: 
2.65
?Enterprise Value
 (TTM)
: 
1.518B  ?EV/FCF
 (TTM)
: 
-4.98
?Dividend Yield
 (TTM)
: 
0%  ?Payout Ratio
 (TTM)
: 
0%
?ROE
 (TTM)
: 
19.88%  ?ROIC
 (TTM)
: 
12.31%
?Net Debt
 (TTM)
: 
-3258732997  ?Debt/Equity
 (TTM)
: 
0
?P/B
 (TTM)
: 
0.52  ?Current Ratio
 (TTM)
: 
30.48

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
N/AResearch AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

Strengths (preview)

  • Robust R&D Pipeline and Innovation Focus: Galapagos demonstrates a strong commitment to research and development, as highlighted in the Q1 2025 earnings call transcript. The company is advancing multiple clinical programs, particularly in immunology and oncology, positioning it as a leader in innovative therapeutic solutions within the biotechnology sector.
  • Strategic Business Restructuring: The decision to separate SpinCo, as noted in the Q1 2025 update, aims to enhance value creation and focus on core therapeutic areas. This strategic move could streamline operations and improve investor confidence in the company’s long-term growth potential.
  • Solid Financial Position: Based on balance sheet data, Galapagos maintains significant cash and cash equivalents alongside total current assets, providing liquidity to fund ongoing R&D and operational needs without immediate financial strain.
  • Positive Industry Positioning: Performance metrics indicate that Galapagos operates in a competitive biotechnology industry within the healthcare sector. Its performance trends (e.g., perf1y, perf5y) suggest alignment with or outperformance of industry averages, reflecting resilience and market relevance.

Log in with Research Access for Weaknesses, Opportunities, Threats, and the complete SWOT.

Log in to continue

Log in with Full Access for the complete SWOT analysis.

Login — it's free

At what price to buy it? -
Intrinsic Value Calculator

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.

[intrinsic_calculator]

Common questions about GLPG valuation

Is Galapagos N.V. (GLPG) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for Galapagos N.V. (GLPG) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is GLPG a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether GLPG trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is GLPG’s P/E ratio?

You can see GLPG’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for GLPG?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is GLPG a good long-term investment?

Whether GLPG fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

GLPG

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

1.71
MARKETSnap

Trading Metrics:

Open: 27.5   Previous Close: 27.51
Day Low: 27.5   Day High: 28.09
Year Low: 24.74   Year High: 37.78
Price Avg 50: 30.32   Price Avg 200: 32.15
Volume: 2385   Average Volume: 153204

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free

GLPG full analysis

06/11/2025

Welcome to MARKETSNAP’s SWOT analysis for Galapagos, a biotech player that’s been making waves in the industry. If you’re not familiar with Galapagos, let me give you the quick rundown. This is a Belgium-based company operating in the biotechnology sector, focusing on developing innovative therapies for inflammatory and fibrotic diseases, among other areas. They’ve carved out a niche in a highly competitive space, and with a decent market cap, they’re not a small fish in the pond. Today, we’re diving…

Open MarketSnap Listen

Log in to continue

Log in to see the full analysis preview and audio links.

Login — it's free

See in Nexus

Relevant news

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
      • Large Caps
      • Absolute
      • Total Market PE
      • Large Caps
      • Absolute
      • Industry
      • Sector
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Philosophy
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlist & Portfolio Watchlist & Portfolio
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read